BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 10818681)

  • 1. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
    Longnecker R
    Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
    Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
    Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2.
    Longnecker R
    Leukemia; 1994 Apr; 8 Suppl 1():S46-50. PubMed ID: 8152303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Epstein-Barr virus latency by latent membrane protein 2.
    Longnecker R; Miller CL
    Trends Microbiol; 1996 Jan; 4(1):38-42. PubMed ID: 8824794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus latent membrane protein 2 effects on epithelial acinus development reveal distinct requirements for the PY and YEEA motifs.
    Fotheringham JA; Raab-Traub N
    J Virol; 2013 Dec; 87(24):13803-15. PubMed ID: 24109232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
    Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).
    Rochford R; Miller CL; Cannon MJ; Izumi KM; Kieff E; Longnecker R
    Arch Virol; 1997; 142(4):707-20. PubMed ID: 9170499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
    Portis T; Cooper L; Dennis P; Longnecker R
    Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
    Rechsteiner MP; Bernasconi M; Berger C; Nadal D
    Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
    Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
    J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
    Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
    J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus: biology and disease.
    Cruchley AT; Williams DM; Niedobitek G; Young LS
    Oral Dis; 1997 May; 3 Suppl 1():S156-63. PubMed ID: 9456681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.
    Garcia P; Harrod A; Jha S; Jenkins J; Barnhill A; Lee H; Thompson M; Williams JP; Barefield J; Mckinnon A; Suarez P; Shah A; Lowrey AJ; Bentz GL
    Antiviral Res; 2021 Apr; 188():105038. PubMed ID: 33577806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus: the first human tumor virus and its role in cancer.
    Pagano JS
    Proc Assoc Am Physicians; 1999; 111(6):573-80. PubMed ID: 10591086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
    Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
    Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
    Price AM; Messinger JE; Luftig MA
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction.
    Miller CL; Lee JH; Kieff E; Burkhardt AL; Bolen JB; Longnecker R
    Infect Agents Dis; 1994; 3(2-3):128-36. PubMed ID: 7812651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization.
    Brielmeier M; Mautner J; Laux G; Hammerschmidt W
    J Gen Virol; 1996 Nov; 77 ( Pt 11)():2807-18. PubMed ID: 8922475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.